All Videos Channels
  1. Novo Nordisk's new obesity drug data disappoints again, shares fall

    Novo Nordisk's new obesity drug data disappoints again, shares fall

    502
  2. Novo Nordisk's Stock Dips: CagriSema Trial Results Shock Investors!

    Novo Nordisk's Stock Dips: CagriSema Trial Results Shock Investors!

    3
    1
  4. BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

    BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

    19
  5. BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

    BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

    27
  6. BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

    BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

    20
  7. BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

    BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

    21
  8. BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

    BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

    18
  9. Novo Nordisk stock plunges on obesity shot trial results

    Novo Nordisk stock plunges on obesity shot trial results

    21
  10. Novo Nordisk stock plunges on obesity shot trial results

    Novo Nordisk stock plunges on obesity shot trial results

    26
  11. Novo Nordisk stock plunges on obesity shot trial results

    Novo Nordisk stock plunges on obesity shot trial results

    20
  12. Novo Nordisk stock plunges on obesity shot trial results

    Novo Nordisk stock plunges on obesity shot trial results

    20
  13. Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

    Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

    20
  14. Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

    Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

    16
  15. Novo Nordisk's New Obesity Drug: Game Changer? #shorts

    Novo Nordisk's New Obesity Drug: Game Changer? #shorts

    12
  16. Novo Nordisk stock plunges on obesity shot trial results

    Novo Nordisk stock plunges on obesity shot trial results

    25
  17. Novo Nordisk stock plunges on obesity shot trial results

    Novo Nordisk stock plunges on obesity shot trial results

    22
  18. Novo Nordisk stock plunges on obesity shot trial results

    Novo Nordisk stock plunges on obesity shot trial results

    20
  19. Novo Nordisk's New Weight Drug Disappoints | World Business Watch

    Novo Nordisk's New Weight Drug Disappoints | World Business Watch

    25